New gene therapy improves the life of 18-year-old with Sickle Cell Disease which affects 5,000 New Jersey residents living with the condition. Skip to Article Set weather ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

Meanwhile, sickle cell gene therapies Casgevy and Lyfgenia cost $2.2 million and $3.1 million, respectively.; More than half of people in the U.S. with sickle cell disease are enrolled in Medicaid ...

SAN DIEGO — A newly approved gene therapy product for sickle cell disease, lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia), led to durable disease remissions for up to 5 years and ...

Until the gene therapy, the only cure for sickle cell disease was a stem cell transplant from a donor. That worked for Wekem after Sylvia discovered she was a match for her younger son.

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models By Bertha Coombs, CNBC • Published February 18, 2025 • Updated on February 18, 2025 at 8:58 am ...

Aaron Scott, of Fayetteville, is the first in North Carolina to receive a new FDA-approved therapy which uses the patient's own cells to relieve the pain of sickle cell disease.

Sebastien Beauzile, the first person in New York to receive Lyfgenia, a gene therapy to treat sickle cell anemia, at Cohen Children's Medical Center on Thursday in New Hyde Park.

More: FDA approves gene therapy for sickle cell disease: 'One incredible journey of success.' Those stem cells can then be collected from the bloodstream and are sent off to a lab, where the cells ...

Gerald Quartey, 18, recently became the first patient to receive Lyfgenia, a one-time, cell-based gene therapy for Sickle Cell Disease for adults and adolescents 12 and older.